安哲祥博士

安彼得醫生是安康癌症中心的資深顧問醫學腫瘤科醫生。其臨床專長涵蓋乳癌治療、乳癌遺傳學、年輕發病乳癌及肺癌領域，擁有逾三十年臨床經驗。

Dr Peter Ang graduated from the National University of Singapore in 1991. He obtained his Master of Medicine (Internal Medicine) and Membership of the Royal College of Physicians (United Kingdom) in 1997. In 2000, he was awarded the Ministry of Health Manpower Development Programme (HMDP) Scholarship to train at Dana Farber Cancer Institute , a teaching affiliate of Harvard Medical School in Boston, USA.

他的專業訓練涵蓋腫瘤學領域，特別專精於乳癌及癌症遺傳學。他亦通過歐洲醫學腫瘤學會（ESMO）為醫學腫瘤科醫師設立的認證考試。2001年，他成為首批通過臨床評估研究所頒發的「家族性癌症風險評估與管理認證考試」資格者，該認證專為癌症遺傳學臨床實踐而設。

Before entering private practice, he was a Senior Consultant Medical Oncologist and Director of the Cancer Education Service (2004) at the National Cancer Centre, Singapore. He was also a visiting consultant to KK Women’s and Children’s Hospital to support the setup of the cancer genetics service, which sees breast, ovarian, and other gynaecological cancer patients. Recognised for his leadership and expertise as a breast cancer specialist doctor, he was the leading cancer specialist of the Breast Cancer Workgroup (2002) for the National Cancer Centre, Singapore, and the SingHealth cluster. He was involved in implementing the cluster Breast Cancer Health Management Plan (2003), incorporating the best breast cancer information with his team of doctors.

Dr Peter Ang was the program leader for Public Cancer Education with SingHealth Cancer Service Development Line (2004). In clinical work, he was awarded the National Excellent Service Award (EXSA) in 2005. He was involved in providing comprehensive oncology information and excellent care for patients with a wide range of cancers, including lung cancer, stomach cancer, colorectal cancer, lymphoma, kidney cancer, breast cancer, ovarian cancer, uterine cancer, and cervical cancer.

他擔任乳癌專書《乳癌病例圖鑑》（2006年）的編輯與主要作者。身為活躍的研究者與癌症專家，安格醫師同時擔任多份權威醫學期刊的審稿人，包括《美國臨床腫瘤學雜誌》、《世界外科腫瘤學雜誌》、《新加坡醫學會年刊》及《腫瘤學期刊》。

He has investigated with collaborators on breast cancer in young women younger than 35 years, non-small cell lung cancer using chemoradiotherapy, irinotecan (CPT-11 or Camptosar) in colorectal cancer patients, gemcitabine with pegylated liposomal doxorubicin (Caelyx, Doxil) as first-line chemotherapy in Asian women with metastatic breast cancer, lapatinib for HER2-positive locally advanced or metastatic breast cancer, and pharmacogenomic and pharmacogenetic studies in Asian breast cancer patients for drugs like doxorubicin, vorinostat and others.

Dr Ang has been a speaker for the Breast Cancer Foundation, the Association of Women Doctors of Singapore, and the Singapore Cancer Society. Recognised as an authority in breast cancer, he was one of the speakers for the first Singapore Medical Oncology Review Course (2007) and the first regional Asian Oncology Summit (2009). He was also one of the regional keynote speakers at the Asia Breast Cancer Collaborative Group Meeting in 2010 and Guangzhou International Breast Cancer Symposium.

He has been actively involved in clinical and translational cancer research for many years, in breast, colon, lung, and other cancers. These have involved international trials of chemotherapy drugs currently in active use and newer targeted therapy drugs such as Herceptin, lapatinib, and sunitinib. He was the principal investigator for more than 10 clinical trials.

Research work by Dr Ang has been published in both local and international journals, including the Journal of Clinical Oncology, Chest, Lancet Oncology, Seminars in Oncology, Cancer Epidemiology Biomarkers & Prevention, Clinical Cancer Research, Clinical Genetics, Pharmacogenomics, and Respiratory Medicine. His work on “Breast-cancer risk in families with mutations in PALB2” was published in the New England Journal of Medicine. (N Engl J Med. 2014 Oct 23;371(17):1650-1)

Dr Ang is fluent in Mandarin, Hokkien, and Teochew dialects. He speaks some Malay and Bahasa and has looked after many Indonesian and Malay patients. He has also looked after Vietnamese, Russian, Myanmar, and Cambodian patients as well, with the help of interpreters.